A systematic, quantitative review of blood autoantibodies in schizophrenia

Schizophrenia Research

Volumn 150, Issue 1, 2013, Pages 245-251

  Ezeoke, Amaka ^a   Mellor, Andrew ^b   Buckley, Peter ^a   Miller, Brian ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b AUGUSTA UNIVERSITY   (United States)

Author keywords

Autoantibody; Autoimmune; Epidemiology; First episode psychosis; Immunology; Meta analysis; Schizophrenia

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; CLOZAPINE; COLD AGGLUTININ; DOPAMINE RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE GROWTH FACTOR; RHEUMATOID FACTOR; SINGLE STRANDED DNA;

ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; AUTOIMMUNE DISEASE; BRIEF PSYCHIATRIC RATING SCALE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; HUMAN; MEDLINE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; PSYCINFO; QUANTITATIVE ANALYSIS; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

AUTOANTIBODY; AUTOIMMUNE; EPIDEMIOLOGY; FIRST-EPISODE PSYCHOSIS; IMMUNOLOGY; META-ANALYSIS; SCHIZOPHRENIA;

AUTOANTIBODIES; DATABASES, BIBLIOGRAPHIC; HUMANS; IMMUNE SYSTEM DISEASES; SCHIZOPHRENIA;

EID: 84884159215     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.07.029     Document Type: Review

References (117)

1. Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhari S., Abbasi S., Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double blind randomized and placebo-controlled trial. Schizophr. Res. 2007, 90(1-3):179-185.
2. Aran A., Lin L., Finn L., et al. Post-streptococcal antibodies are associated with metabolic syndrome in a population-based cohort. PLoS One 2011, 6(9):e25017.
3. Arolt V., Weitzch C., Wilke I., et al. Production of interferon-gamma in families with multiple occurrence of schizophrenia. Psychiatry Res. 1997, 66(2-3):145-152.
4. Barry S., Clarke G., Scully P., Dinan T. Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J. Psychopharmacol. 2009, 23(3):287-294.
5. Benros M.E., Nielsen P.R., Nordentoft M., Eaton W.W., Dalton S.O., Mortensen P.B. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am. J. Psychiatry 2011, 168(12):1303-1310.
6. Berglund S., Gottfries C.G., Gottfries I., Stormby K. Chlorpromazine-induced antinuclear factors. Acta Med. Scand. 1970, 187(1-2):67-74.
7. Bilici M., Tekelioglu Y., Efendioglu S., Ovali E., Ulgen M. The influence of olanzapine on immune cells in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27(3):483-485.
8. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 2010, 167(3):261-280.
9. Cabrera De Leon A., Almeida Gonzalez D., Almeida A., et al. Factors associated with parietal cell autoantibodies in the general population. Immunol. Lett. 2012, 147(1-2):63-66.
10. Canoso R.T., de Oliveira R.M., Nixon R. Neuroleptic associated autoantibodies a prevalence study. Biol. Psychiatry 1990, 27(8):863-870.
11. Cascella N.G., Kryszak D., Bushra B., Gregory P., Kelly D.L., McEvoy J.P., et al. Presence of celiac disease and gluten sensitivity in the united states clinical antipsychotic trials of intervention effectiveness study population. Schizophr. Bull. 2011, 37(1):94-100.
12. Chandley M., Miller M.N., Newell Kwasigroch C., Wilson T.D., Miller B.E. Increased antibodies for the alpha 7 subunit of the nicotinic receptor in schizophrenia. Schizophr. Res. 2009, 109(1-3):98-101.
13. Chen C.R., Hamidi S., Braley-Mullen H., Nagayama Y., Bresee C., Aliesky H.A., et al. Antibodies to thyroid peroxidase arise spontaneously with age in NOD.H-2h4 mice and appear after thyroglobulin antibodies. Endocrinology 2010, 151(9):4583-4593.
14. Chen S.J., Chao Y.L., Chen C.Y., Chang C.M., Wu E.C., Wu C.S., Yeh H.H., Chen C.H., Tsai H.J. Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study. Br. J. Psychiatry 2012, 200(5):374-380.
15. Chengappa K.N.R., Carpenter A.B., Keshavan M.S., Yang Z.W., Kelly R.H., Rabin B.S., et al. Elevated IgG and IgM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients. Biol. Psychiatry 1991, 30(7):731-735.
16. Chengappa K.N.R., Carpenter A.B., Yang Z.W., Brar J.S., Rabin B.S., Ganguli R. Elevated IgG antihistone antibodies in a subgroup of medicated schizophrenic patients. Schizophr. Res. 1992, 7(1):49-54.
17. Chengappa K.N.R., Yang Z.W., Schurin G., Farooqui S.M., Rabin B.S., Ganguli R. Antibodies to D-2 Receptor in neuroleptic-naïve schizophrenic patients. Biol. Psychiatry 1993, 33:97A.
18. Chengappa K.N.R., Ganguli R., Yang Z.W., Shurin G., Brar J.S., Rabin B.S. Impaired mitogen (PHA) responsiveness and increased autoantibodies in Caucasian schizophrenic patients with the HLA B8/DR3 phenotype. Biol. Psychiatry 1995, 37(8):546-549.
19. Cochran W.B. The comparison of percentages in matched samples. Biometrika 1950, 37(3-4):256-266.
20. Cohen D., Batstra M.R., Gispen-de Wied C.C. Immunological characteristics of diabetes in schizophrenia. Diabetologia 2005, 48(9):1941-1942.
21. Dinarello C.A. The many worlds of reducing interleukin-1. Arthritis Rheum. 2005, 52(7):1960-1967.
22. Eaton W., Byrne M., Ewald H., et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am. J. Psychiatry 2006, 163(3):521-528.
23. Eaton W., Pederson M., Nielsen P., Mortensen P. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010, 12(6):638-646.
24. Firer M., Sirota P., Schild K., Elizur A., Slor H. Anticaridiolipin antibodies are elevated in drug free, multiply affected families with schizophrenia. J. Clin. Immunol. 1994, 14(1):73-78.
25. Flatow J., Buckley P., Miller B. Meta-analysis of oxidative stress in schizophrenia. Biol. Psychiatry 2013, (http://dx.doi.org/10.1016/j.biopsych.2013.03.018. in press).
26. Ganguli R., Rabin B.S. CD5 positive B lymphocytes in schizophrenia: no alteration in numbers or percentage as compared with control subjects. Psychiatry Res. 1993, 48(1):69-78.
27. Ganguli R., Brar J.S., Solomon W., Chengappa K.N., Rabin B.S. Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production. Psychiatry Res. 1992, 44(2):113-123.
28. Gilvarry C., Sham P., Jones P., et al. Family history of autoimmune diseases in psychosis. Schizophr. Res. 1996, 19(1):33-40.
29. Greenfield J.R., McGrath M., Kossard S., Charlesworth J.A., Campbell L.V. ANCA-positive vasculitis induced by thioridzine: confirmed by rechallenge. Br. J. Dermatol. 2002, 147(6):1265-1267.
30. Gottfries C.G., Gottfries I. Antinuclear factors in relation to age, sex, mental disease and treatment with phenothiazines. Acta. Psychiatr. Scand. Suppl. 1974, 255:193-201.
31. Halacheva K., Dimova S., Tolev T., Dimov D., Nikolova M. Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication. Psychiatry Res. 2009, 169(1):51-55.
32. Hanifi-Moghaddam P., Schloot N., Kappler S., Seissler J., Kolb H. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 2003, 52(5):1137-1142.
33. Haussleiter I.S., Emons B., Schaub M., Borowski K., Brüne M., Wandinger K.P., et al. Investigation of antibodies against synaptic proteins in a cross-sectional cohort of psychotic patients. Schizophr. Res. 2012, 140(1-3):258-259.
34. Hinze-Selch D., Becker E.W., Stein G.M., Berg P.A., Mullington J., Holsboer F., et al. Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology 1998, 19(2):114-122.
35. Hunter J., Schmidt F. Fixed effects vs. random effects meta-analysis models: implications for cumulative research knowledge. Int. J. Sel. Assess. 2000, 8:275-292.
36. International Schizophrenia Consortium, Pulcell S., Wray N., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460(7256):748-752.
37. Jin S.Z., Wu N., Xu Q., Zhang X., Ju G.Z., Law M.H., Wei J. A study of circulating gliadin antibodies in schizophrenia among a Chinese population. Schizophr. Bull. 2012, 38(3):514-518.
38. Kanjolia A., Valigorsky J.M., Joson-Pasion M.L. Clozaril-induced lupus anticoagulant. Am. J. Hematol. 1997, 54(4):345-346.
39. Kilidireas K., Latov N., Strauss D.H., Gorig A.D., Hashim G.A., Gorman J.M., et al. Antibodies to the human 60kDa heat-shock protein in patients with schizophrenia. Lancet 1992, 340(8819):569-572.
40. Klyushnik T.P., Danilovskaya E.V., Vatolkina O.E., Turkova I.L., Tsutsul'kovskaya M.Ya., Orlova V.A., et al. Changes in the serum levels of autoantibody to nerve growth factor in patients with schizophrenia. Neurosci. Behav. Physiol. 1999, 29(3):355-357.
41. Kolyaskina G., Burbaeva O., Tsutsulkovskaya M. Circulating immune complexes and autoantibodies in schizophrenia. Schizophr. Res. 1999, 36:106.
42. Kuwana M., Okano Y., Kaburaki J., Tojo T., Medsger T. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum. 1994, 37(6):902-906.
43. Laan W., Grobbee D., Selte J., Heijnen C., Kahn R., Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo controlled trial. J. Clin. Psychiatry 2010, 71(5):520-527.
44. Laske C., Zank M., Klein R., Stransky E., Batra A., Buchkremer G., et al. Autoantibody reactivity in serum of patients with major depression, schizophrenia and healthy controls. Psychiatry Res. 2008, 158(1):83-86.
45. Levine J., Susnovski M., Handzel Z., Leykin I., Shinitzky M. Treatment of schizophrenia with an immunosuppressant. Lancet 1994, 344(8918):59-60.
46. Mantovani C., Louzada-Junior P., Nunes E.A., de Figueiredo F.P., Oliveira G.R., Del-Ben C.M. Antinuclear antibodies testing as a routine screening for systemic lupus erythematosus in patients presenting first-episode psychosis. Early Interv. Psychiatry 2012, 6(3):322-325.
47. Masdeu J.C., González-Pinto A., Matute C., Ruiz De Azúa S., Palomino A., De Leon J., Berman K.F., Dalmau J. Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. Am. J. Psychiatry 2012, 169(10):1120-1121.
48. McAllister C., Rapaport M., Pickar D., et al. Increased numbers of CD5+ B lymphocytes in schizophrenic patients. Arch. Gen. Psychiatry 1989, 46(10):890-894.
49. Mellsop G., Whittingham S., Ungar B. Schizophrenia and autoimmune serological reactions. Arch. Gen. Psychiatry 1973, 28(2):194-196.
50. Mellsop G., Whittingham S., Ungar B. Anticardiolipin antibodies in a sample of chronic schizophrenics receiving neuroleptic therapy. South. Med. J. 1994, 87(2):190-192.
51. Messias E., Chen C., Eaton W. Epidemiology of schizophrenia: review of findings and myths. Psychiatr. Clin. North Am. 2007, 30(3):323-338.
52. Miller B., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
53. Miller B., Gassama B., Sebastian D., Buckley P., Mellor A. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2012, 73(10):993-999.
54. Miller B.J., Culpepper N., Rapaport M.H. C-reactive protein in schizophrenia: a review and meta-analysis. Clin. Schizophr. Relat. Psychoses 2013, (in press).
55. Muller N., Riedel M., Scheppach C., et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry 2002, 159(6):1029-1034.
56. Muller N., Krause D., Dehning S., et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, doubleblind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 2010, 121(1-3):118-124.
57. Nilsson L., Linderholm K., Engberg G., et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr. Res. 2005, 80(2-3):315-322.
58. Oken R.J., Schulzer M. At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophr. Bull. 1999, 25(4):625-638.
59. Oreskes I., Rosenblatt S., Spiera H., Meadow H. Rheumatoid factors in an acute psychiatric population. Ann. Rheum. Dis. 1968, 27(1):60-63.
60. Ortega-Hernandez O.D., Kivity S., Shoenfeld Y. Olfaction, psychiatric disorders and autoimmunity: is there a common genetic association?. Autoimmunity 2009, 42(1):80-88.
61. Othman S.S., Abdul Kadir K., Hassan J., Hong G.K., Singh B.B., Raman N. High prevalence of thyroid function test abnormalities in chronic schizophrenia. Aust. N. Z. J. Psychiatry 1994, 28(4):620-624.
62. Padmos R.C., Bekris L., Knijff E.M., Tiemeier H., Kupka R.W., Cohen D., et al. A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. Biol. Psychiatry. 2004, 56(7):476-482.
63. Pelonero A.L., Pandurangi A.K., Calabrese V.P. Autoantibodies to brain lipids in schizophrenia. Am. J. Psychiatry 1990, 147(5):661-662.
64. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63(8):801-808.
65. Poyraz B.C., Aksoy C., Balcioǧlu I. Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinemia. Eur. Neuropsychopharmacol. 2008, 18(9):667-672.
66. Printz D., Strauss D., Goetz R., et al. Elevation of CD5+ B lymphocytes in schizophrenia. Biol. Psychiatry 1999, 46(1):110-118.
67. Quismorio F.P., Bjarnason D.F., Kiely W.F., Dubois E.L., Friou G.J. Antinuclear antibodies in chronic psychotic patients treated with chlorpromazine. Am. J. Psychiatry 1975, 132(11):1204-1206.
68. Ravikumar A., Deppadevi K., Arun P., Manojkumar V., Kurup P. Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders. Neurol. India 2000, 48(3):231-238.
69. Redolf S., Schlenke P., Broocks A., et al. Search for atypical lymphocytes in schizophrenia. World J. Biol. Psychiatry 2004, 5(1):33-37.
70. Reichelt K.L., Landmark J. Specific IgA antibody increases in schizophrenia. Biol. Psychiatry 1995, 37(6):410-413.
71. Rhoads J., Guirgis H., McKnight C., Duchemin A.M. Lack of anti-NMDA receptor autoantibodies in the serum of subjects with schizophrenia. Schizophr. Res. 2011, 129(2-3):213-214.
72. Sathyasaikumar K., Stachowski E., Wonodi I., et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr. Bull. 2011, 37(6):1147-1156.
73. Schott K., Batra A., Klein R., Bartels M., Koch W., Berg P.A. Antibodies against serotonin and gangliosides in schizophrenia and major depressive disorder. Eur. Psychiatry 1992, 7:209-212.
74. Schott K., Uhl A., Batra A., Bartels M., Eusterschulte B., Buchkremer G. Antinuclear antibodies in schizophrenia and major depressive disorder-a lasting puzzle. Eur. Psychiatry 1996, 11(5):263-267.
75. Schwartz M., Rochas M., Weller B., Sheinkman A., Tal I., Golan D., et al. High association of anticardiolipin antibodies with psychosis. J. Clin. Psychiatry 1998, 59(1):20-23.
76. Schwartz M., Rochas M., Toubi E., Sharf B. The presence of lupus anticoagulant and anticardiolipin antibodies in patients undergoing long-term neuroleptic treatment. J. Psychiatry Neurosci. 1999, 24(4):351-352.
77. Schwarz M.J., Riedel M., Gruber R., Ackenheil M., Müller N. Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease. Am. J. Psychiatry 1999, 156(7):1103-1104.
78. Schwartz M., Kormilachev M., Kushnir M., Weller B., Rochas M., Toubi E. Lupus anticoagulant and anticardiolipin antibodies in serum of patients treated with risperidone. J. Clin. Psychiatry. 2009, 70(5):769-771.
79. Shcherbakova I.V., Siryachenko T.M., Mazaeva N.A., Kaleda V.G., Krasnolobova S.A., Klyushnik T.P. Leukocyte elastase and autoantibodies to nerve growth factor in the acute phase of schizophrenia and their relationship to symptomatology. World J. Biol. Psychiatry 2004, 5(3):143-148.
80. Shen H., Li R., Xiao H., Zhou Q., Cui Q., Chen J. Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients. J. Psychiatr. Res. 2009, 43(6):615-619.
81. Shi J., Levinson D., Duan J., et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460(7256):753-757.
82. Shopsin B., Sathananthan G.L., Chan T.L., Kravitz H., Gershon S. Antinuclear factor in psychiatric patients. Biol. Psychiatry 1973, 7(2):81-87.
83. Sidhom O., Laadhar L., Zitouni M., Ben Alaya N., Rafrafi R., Kallel-Sellami M., et al. Spectrum of autoantibodies in Tunisian psychiatric inpatients. Immunol. Invest. 2012, 41(5):538-549.
84. Sirota P., Firer M.A., Schild K., Tanay A., Elizur A., Meytes D., et al. Autoantibodies to DNA in multicase families with schizophrenia. Biol. Psychiatry 1993, 33(6):450-455.
85. Sirota P., Firer M., Schild K., Zurgil N., Barak Y., Elizur A., et al. Increased anti-Sm antibodies in schizophrenic patients and their families. Prog. Neuropsychopharmacol. Biol. Psychiatry 1993, 17(5):793-800.
86. Sirota P., Bogdanov I., Katzav A., Hershko R., Chapman J. Reduced anticardiolipin antibodies in first episode and chronic schizophrenia. Psychiatry Res. 2006, 144(2-3):211-216.
87. Sokol D.K., O'Brien R.S., Wagenknecht D.R., Rao T., McIntyre J.A. Antiphospholipid antibodies in blood and cerebrospinal fluids of patients with psychosis. J. Neuroimmunol. 2007, 190(1-2):151-156.
88. Song C., Merali Z., Anisman H. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience 1999, 88(3):823-836.
89. Song F., Sheldon T.A., Sutton A.J., Abrams K.R., Jones D.R. Methods for exploring heterogeneity in meta-analysis. Eval. Health Prof. 2001, 24(2):126-151.
90. Spivak B., Radwan M., Elimelech D., Molcho A., Avidan G., Ohring R., et al. Cold agglutinin titers in psychiatric patients. Am. J. Psychiatry 1988, 145(11):1460-1461.
91. Spivak B., Radwan M., Bartur P., Mester R., Weizman A. Antinuclear autoantibodies in chronic schizophrenia. Acta Psychiatr. Scand. 1995, 92(4):266-269.
92. Stefannson H. Common variants conferring risk of schizophrenia. Nature 2009, 460(7256):744-747.
93. Steiner J., Jacobs R., Panteli B., et al. Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity. Eur. Arch. Psychiatry Clin. Neurosci. 2010, 260(7):509-518.
94. Steiner J., Walter M., Glanz W., Sarnyai Z., Bernstein H.G., Vielhaber S., et al. Increased prevalence of diverse N-methyl-d-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-d-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013, 70(3):271-278.
95. Stevens A., Weller M. Ganglioside antibodies in schizophrenia and major depression. Biol. Psychiatry 1992, 32(8):728-730.
96. Sundin U., Thelander S. Antibody reactivity to brain membrane proteins in serum from schizophrenic patients. Brain Behav. Immun. 1989, 3(4):345-358.
97. Szodoray P., Szabo Z., Kapitany A., et al. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun. Rev. 2010, 9(3):140-143.
98. Tanaka S., Matsunaga H., Kimura M., Tatsumi K., Hidaka Y., Takano T., et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J. Neuroimmunol. 2003, 141(1-2):155-164.
99. Teplizki H.A., Sela B., Shoenfeld Y. Autoantibodies to brain and polynucleotides in patients with schizophrenia: a puzzle. Immunol. Res. 1992, 11(1):66-73.
100. Toubi E., Shoenfeld Y. Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun. Rev. 2007, 6(3):119-125.
101. Vargas-Alarcon G., Yamamoto-Furusho J.K., Zuniga J., Canoso R., Granados J. HLA-DR7 in association with chlorpromazine-induced lupus anticoagulant (LA). J. Autoimmun. 1997, 10(6):579-583.
102. Villemain F., Magnin M., Feuillet-Fieux M.N., Zarifian E., Loo H., Bach J.F. Anti-histone antibodies in schizophrenia and affective disorders. Psychiatry Res. 1988, 24(1):53-60.
103. Villemain F., Chatenoud L., Galinowski A., Homo-Delarche F., Ginestet D., Loo H., Aberrant T., et al. Cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am. J. Psychiatry 1989, 146(5):609-616.
104. von Brauchitsch H. Antinuclear factor in psychiatric disorders. Am. J. Psychiatry 1972, 128(12):1552-1554.
105. von Kirchbach A., Rischer E., Kornhuber H. Failure to detect dopamine receptor IgG autoantibodies in sera of schizophrenic patients. Short note. J. Neural Transm. 1987, 70(1-2):175-179.
106. Wang X.F., Wang D., Zhu W., Delrahim K.K., Dolnak D., Rapaport M.H. Studies characterizing 60kDa autoantibodies in subjects with schizophrenia. Biol. Psychiatry 2003, 53(5):361-375.
107. Xavier R.M., Yamauchi Y., Nakamura M., Tanigawa Y., Ishikura H., Tsunematsu T., et al. Antinuclear antibodies in healthy aging people: a prospective study. Mech. Ageing. Dev. 1995, 78(2):145-154.
108. Yang Z.W., Chengappa K.N., Shurin G., Brar J.S., Rabin B.S., Gubbi A.V., et al. An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia. Psychol. Med. 1994, 24(2):449-455.
109. Yannitsi S.G., Manoussakis M.N., Mavridis A.K., Tzioufas A.G., Loukas S.B., Plataris G.K., et al. Factors related to the presence of autoantibodies in patients with chronic mental disorders. Biol. Psychiatry 1990, 27(7):747-756.
110. Yao J., Keshavan M. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid. Redox Signal. 2011, 15(7):2011-2035.
111. Yarlagadda A., Helvink B., Chou C., Gladieux K., Keller A., Clayton A. Glutamic acid decarboxylase (GAD) antibodies in tardive dyskinesia (TD) as compared to patients with schizophrenia without TD and normal controls. Schizophr. Res. 2008, 105(1-3):287-288.
112. Yarlagadda A., Taylor J.H., Hampe C.S., Alfson E., Clayton A.H. GAD65 antibodies, chronic psychosis, and type 2 diabetes mellitus. Innov. Clin. Neurosci. 2011, 8(8):34-36.
113. Zalcman S., Green-Johnson J., Murray L., et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res. 1994, 643(1-2):40-49.
114. Zalcman S., Savina I., Wise R. Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats. Brain Res. 1999, 847(2):276-283.
115. Zandi M.S., Irani S.R., Lang B., Waters P., Jones P.B., McKenna P., et al. Disease relevant autoantibodies in first episode schizophrenia. J. Neurol. 2011, 258(4):686-688.
116. Zarrabi M.H., Zucker S., Miller F., Derman R.M., Romano G.S., Hartnett J.A., et al. Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann. Intern. Med. 1979, 91(2):194-199.
117. Zorrilla E.P., Cannon T.D., Gur R.E., Kessler J. Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability or disease?. Biol. Psychiatry 1996, 40(9):825-833.